Recent Updates
Recently added Catalysts

NNC0721-5186

Phase 1

Overweight | Small Molecules | Other |Novo Nordisk A/S|Trials Updated: Nov 17, 2026

NNC0721-5186 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment102

FDA Designations

No designations recorded

NNC0721-5186 clinical trials

NNC0721-5186 · 1 trial · 2 indications

Phase 1 1
NCT07940582A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or ObesityOverweight
NOT YET_RECRUITING102 Analytics
PHASE1NOT YET_RECRUITING
A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or Obesity
OverweightUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of treatment-emergent adverse events (TEAEs)
From time of dosing (Day 1) to Day 36

Measured in number of events.

Secondary Endpoints

AUC: Area under the NNC0721-5186 plasma concentration-time curve
From pre-dose (Day 1) to Day 36
Cmax: Maximum observed NNC0721-5186 plasma concentration
From pre-dose (Day 1) to Day 36
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
NNC0721-5186EXPERIMENTALParticipants will receive a single ascending subcutaneous dose of NNC0721-5186.
SemaglutideACTIVE_COMPARATORParticipants will receive a single ascending subcutaneous dose of semaglutide up to 3 doses.
PlaceboPLACEBO_COMPARATORParticipants will receive a single ascending subcutaneous dose of placebo matched to NNC0721-5186.

Interventions

NameTypeDescription
NNC0721-5186DRUGNNC0721-5186 is administered as a single subcutaneous injection.
SemaglutideDRUGSemaglutide is administered as a single subcutaneous injection using a pen-injector.
Placebo (NNC0721-5186)DRUGPlacebo is administered as a single subcutaneous injection matching NNC0721-5186.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexFEMALE
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Female (sex at birth). 2. Age 18 to 55 years (both inclusive) at the time of signing the informed consent. 3. Body Mass Index 25.0 to 39.9 kg/m\^2 (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator. 4. Considered eligible...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 17, 2026NCT07940582NEW_TRIAL: changed
LOWNov 17, 2026NCT07940582NEW_TRIAL: changed